nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

18.07.2023 | Research

Hospital volume and prognosis of patients with metastatic pancreatic cancer: A study using the Osaka Cancer Registry

verfasst von: Yasuharu Kawamoto, Kenji Ikezawa, Takahiro Tabuchi, Toshitaka Morishima, Yusuke Seiki, Ko Watsuji, Takeru Hirao, Sena Higashi, Makiko Urabe, Yugo Kai, Ryoji Takada, Takuo Yamai, Kaori Mukai, Tasuku Nakabori, Hiroyuki Uehara, Isao Miyashiro, Kazuyoshi Ohkawa

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 14/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Pancreatic cancer (PC) has one of the worst prognoses among all solid cancers. Hospital volume has been shown to be significantly associated with outcomes in patients with PC undergoing surgery. Nonetheless, the association between hospital volume and prognosis in patients with metastatic PC remains unclear. This study aimed to examine the association between hospital volume and prognosis in patients with metastatic PC using large-scale population-based cancer registry data.

Methods

This retrospective observational study was conducted using data from the Osaka Cancer Registry database. Data of patients with metastatic PC over 10 years (2009–2018) were obtained. Hospitals were categorized into high-volume hospitals (HVHs; ≥ 240 patients diagnosed with PC for 10 years), middle-volume hospitals (MVHs; 120–239 patients diagnosed with PC for 10 years), and low-volume hospitals (LVHs; < 120 patients diagnosed with PC for 10 years). Multivariate analysis was performed to identify factors associated with overall survival (OS).

Results

The analysis included 8,929 patients with metastatic PC. Median OS was significantly more favorable in HVHs than in MVHs and LVHs. Multivariate analysis adjusted for hospital volume, age, primary tumor site, year of diagnosis, chemotherapy, and radiotherapy revealed that hospital volume was an independent factor associated with OS (HVHs vs. MVHs: hazard ratio [HR], 1.10; 95% confidence interval [CI], 1.03–1.16; P = 0.003, HVHs vs. LVHs: HR, 1.20; 95% CI, 1.13–1.27; P < 0.001).

Conclusion

Hospital volume is an independent prognostic factor in patients with metastatic PC, suggesting an association between hospital volume and treatment outcomes.

Nur mit Berechtigung zugänglich

Acher AW, Weber SM, Pawlik TM (2022) Does the volume-outcome association in pancreas cancer surgery justify regionalization of care? A review of current controversies. Ann Surg Oncol 29:1257–1268. https://doi.org/10.1245/s10434-021-10765-wCrossRefPubMed

Addeo P, Delpero JR, Paye F et al (2014) Pancreatic fistula after a pancreaticoduodenectomy for ductal adenocarcinoma and its association with morbidity: a multicentre study of the French Surgical Association. HPB (Oxford) 16:46–55. https://doi.org/10.1111/hpb.12063CrossRefPubMed

Atallah C, Oduyale O, Stem M, Eltahir A, Almaazmi HH, Efron JE, Safar B (2021) Are academic hospitals better at treating metastatic colorectal cancer? Surgery 169:248–256. https://doi.org/10.1016/j.surg.2020.05.023CrossRefPubMed

Bader NA, Sweeney M, Zeymo A, Villano AM, Houlihan B, Bayasi M, Al-Refaie WB, Chan KS (2022) Defining a minimum hospital volume threshold for minimally invasive colon cancer resections. Surgery 171:293–298. https://doi.org/10.1016/j.surg.2021.06.031CrossRefPubMed

Baumrucker CC, Spring SR, Cohen BL, Millen JC, Macedo FI, Franceschi D (2021) The effect of hospital volume on outcomes of patients with occult breast cancer. Ann Surg Oncol 28:2128–2135. https://doi.org/10.1245/s10434-020-09103-3CrossRefPubMed

Besseling J, Reitsma J, Van Erkelens JA et al (2021) Use of palliative chemotherapy and ICU admissions in gastric and esophageal cancer patients in the last phase of life: a nationwide observational study. Cancers (Basel) 13:145. https://doi.org/10.3390/cancers13010145CrossRefPubMed

Cortez NE, Mackenzie GG (2021) Ketogenic diets in pancreatic cancer and associated cachexia: cellular mechanisms and clinical perspectives. Nutrients 13:3202. https://doi.org/10.3390/nu13093202CrossRefPubMedPubMedCentral

Daiku K, Ikezawa K, Morishima T, Kai Y, Takada R, Yamai T, Miyashiro I, Ohkawa K (2022) Chemotherapy effectiveness and age-group analysis of older adult patients with metastatic pancreatic cancer: a Japanese cancer registry cohort study. J Geriatr Oncol 13:1208–1215. https://doi.org/10.1016/j.jgo.2022.07.010CrossRefPubMed

De Dosso S, Siebenhüner AR, Winder T, Meisel A, Fritsch R, Astaras C, Szturz P, Borner M (2021) Treatment landscape of metastatic pancreatic cancer. Cancer Treat Rev 96:102180. https://doi.org/10.1016/j.ctrv.2021.102180

Fukuda J, Ikezawa K, Nakao M et al (2021) Predictive factors for pancreatic cancer and its early detection using special pancreatic ultrasonography in high-risk individuals. Cancers (Basel) 13:502. https://doi.org/10.3390/cancers13030502CrossRefPubMedPubMedCentral

Gani F, Johnston FM, Nelson-Williams H, Cerullo M, Dillhoff ME, Schmidt CR, Pawlik TM (2017) Hospital volume and the costs associated with surgery for pancreatic cancer. J Gastrointest Surg 21:1411–1419. https://doi.org/10.1007/s11605-017-3479-xCrossRefPubMed

Gooiker GA, Lemmens VE, Besselink MG et al (2014) Impact of centralization of pancreatic cancer surgery on resection rates and survival. Br J Surg 101:1000–1005. https://doi.org/10.1002/bjs.9468CrossRefPubMed

Goyal G, Kommalapati A, Bartley AC, Gunderson TM, Adjei AA, Go RS (2018) Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer. Lung Cancer 122:214–219. https://doi.org/10.1016/j.lungcan.2018.06.025CrossRefPubMed

Greenup RA, Obeng-Gyasi S, Thomas S, Houck K, Lane WO, Blitzblau RC, Hyslop T, Hwang ES (2018) The effect of hospital volume on breast cancer mortality. Ann Surg 267:375–381. https://doi.org/10.1097/SLA.0000000000002095CrossRefPubMed

Haj Mohammad N, Bernards N, Besselink MG et al (2016) Volume matters in the systemic treatment of metastatic pancreatic cancer: a population-based study in the Netherlands. J Cancer Res Clin Oncol 142:1353–1360. https://doi.org/10.1007/s00432-016-2140-5CrossRefPubMedPubMedCentral

Iwatsuki M, Yamamoto H, Miyata H, Kakeji Y, Yoshida K, Konno H, Seto Y, Baba H (2021) Association of surgeon and hospital volume with postoperative mortality after total gastrectomy for gastric cancer: data from 71,307 Japanese patients collected from a nationwide web-based data entry system. Gastric Cancer 24:526–534. https://doi.org/10.1007/s10120-020-01127-8CrossRefPubMed

Ju MR, Blackwell JM, Zeh HJ, Yopp AC, Wang SC, Porembka MR (2021) Redefining high-volume gastric cancer centers: the impact of operative volume on surgical outcomes. Ann Surg Oncol 28:4839–4847. https://doi.org/10.1245/s10434-021-09655-yCrossRefPubMed

Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458. https://doi.org/10.1038/bmt.2012.244CrossRefPubMed

Kemp Bohan PM, Chang SC, Grunkemeier GL, Spitzer HV, Carpenter EL, Adams AM, Vreeland TJ, Nelson DW (2023) Impact of mediating and confounding variables on the volume-outcome association in the treatment of pancreatic cancer. Ann Surg Oncol 30:1436–1448. https://doi.org/10.1245/s10434-022-12908-zCrossRefPubMed

Matsuda S (2019) Health policy in Japan – current situation and future challenges. JMA J 2:1–10. https://doi.org/10.31662/jmaj.2018-0016

Mizrahi JD, Surana R, Valle JW, Shroff RT (2020) Pancreatic cancer. Lancet 395:2008–2020. https://doi.org/10.1016/S0140-6736(20)30974-0CrossRefPubMed

Morishima T, Sato A, Nakata K, Miyashiro I (2020) Geriatric assessment domains to predict overall survival in older cancer patients: an analysis of functional status, comorbidities, and nutritional status as prognostic factors. Cancer Med 9:5839–5850. https://doi.org/10.1002/cam4.3205CrossRefPubMedPubMedCentral

Morishima T, Sato A, Nakata K et al (2021) Barthel index-based functional status as a prognostic factor in young and middle-aged adults with newly diagnosed gastric, colorectal and lung cancer: a multicentre retrospective cohort study. BMJ Open 11:e046681. https://doi.org/10.1136/bmjopen-2020-046681CrossRefPubMedPubMedCentral

Muranaka T, Kuwatani M, Komatsu Y et al (2017) Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. J Gastrointest Oncol 8:566–571. https://doi.org/10.21037/jgo.2017.02.02

Odani S, Tabuchi T, Nakata K et al (2022) Incidence and relative risk of metachronous second primary cancers for 16 cancer sites, Osaka, Japan, 2000–2015: population-based analysis. Cancer Med 11:507–519. https://doi.org/10.1002/cam4.4457CrossRefPubMed

Okusaka T, Furuse J (2020) Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. J Gastroenterol 55:369–382. https://doi.org/10.1007/s00535-020-01666-yCrossRefPubMedPubMedCentral

Okusaka T, Nakamura M, Yoshida M et al (2020) Clinical practice guidelines for pancreatic cancer 2019 from the Japan Pancreas Society: a synopsis. Pancreas 49:326–335. https://doi.org/10.1097/MPA.0000000000001513CrossRefPubMed

Ratnayake B, Pendharkar SA, Connor S, Koea J, Sarfati D, Dennett E, Pandanaboyana S, Windsor JA (2022) Patient volume and clinical outcome after pancreatic cancer resection: a contemporary systematic review and meta-analysis. Surgery 172:273–283. https://doi.org/10.1016/j.surg.2021.11.029CrossRefPubMed

Sasaki T, Kanata R, Yamada I, Matsuyama M, Ozaka M, Sasahira N (2019) Improvement of treatment outcomes for metastatic pancreatic cancer: A real-world data analysis. In Vivo 33:271–276. https://doi.org/10.21873/invivo.11471

Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7–33. https://doi.org/10.3322/caac.21708CrossRefPubMed

Stoltzfus KC, Shen B, Tchelebi L, Trifiletti DM, Gusani NJ, Walter V, Wang M, Zaorsky NG (2021) Impact of facility surgical volume on survival in patients with cancer. J Natl Compr Canc Netw 19:495–503. https://doi.org/10.6004/jnccn.2020.7644CrossRefPubMed

Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25:2607–2615. https://doi.org/10.1200/JCO.2006.09.2551CrossRefPubMed

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660CrossRefPubMed

Tabuchi T, Ito Y, Ioka A, Miyashiro I, Tsukuma H (2012) Incidence of metachronous second primary cancers in Osaka, Japan: update of analyses using population-based cancer registry data. Cancer Sci 103:1111–1120. https://doi.org/10.1111/j.1349-7006.2012.02254.xCrossRefPubMedPubMedCentral

Tezuka K, Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Ohgi K, Uesaka K (2021) The influence of familial pancreatic cancer on postoperative outcome in pancreatic cancer: relevance to adjuvant chemotherapy. J Gastroenterol 56:101–113. https://doi.org/10.1007/s00535-020-01730-7CrossRefPubMed

Tonini V, Zanni M (2021) Pancreatic cancer in 2021: what you need to know to win. World J Gastroenterol 27:5851–5889. https://doi.org/10.3748/wjg.v27.i35.5851CrossRefPubMedPubMedCentral

Toyoda Y, Tabuchi T, Nakata K, Morishima T, Nakayama T, Miyashiro I, Hojo S, Yoshioka S (2018a) Increase in incidental detection of thyroid cancer in Osaka, Japan. Cancer Sci 109:2310–2314. https://doi.org/10.1111/cas.13645CrossRefPubMedPubMedCentral

Toyoda Y, Tabuchi T, Nakayama T, Hojo S, Yoshioka S, Wakabayashi Y, Maeura Y (2018b) Trends in the clinical stage distribution of breast cancer in Osaka, Japan. Breast Cancer 25:250–256. https://doi.org/10.1007/s12282-017-0807-7CrossRefPubMed

Vrijens F, Stordeur S, Beirens K, Devriese S, Van Eycken E, Vlayen J (2012) Effect of hospital volume on processes of care and 5-year survival after breast cancer: a population-based study on 25000 women. Breast 21:261–266. https://doi.org/10.1016/j.breast.2011.12.002CrossRefPubMed

Wolfson JA, Sun CL, Wyatt LP, Hurria A, Bhatia S (2015) Impact of care at comprehensive cancer centers on outcome: results from a population-based study. Cancer 121:3885–3893. https://doi.org/10.1002/cncr.29576CrossRefPubMed

Wu D, Wang X, Shi G, Sun H, Ge G (2021) Prognostic and clinical significance of modified Glasgow prognostic score in pancreatic cancer: a meta-analysis of 4,629 patients. Aging (Albany, NY) 13:1410–1421. https://doi.org/10.18632/aging.202357

Yamai T, Ikezawa K, Hiraga E et al (2022) Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel. PLOS ONE 17:e0264653. https://doi.org/10.1371/journal.pone.0264653CrossRefPubMedPubMedCentral

Titel: Hospital volume and prognosis of patients with metastatic pancreatic cancer: A study using the Osaka Cancer Registry
verfasst von: Yasuharu Kawamoto
Kenji Ikezawa
Takahiro Tabuchi
Toshitaka Morishima
Yusuke Seiki
Ko Watsuji
Takeru Hirao
Sena Higashi
Makiko Urabe
Yugo Kai
Ryoji Takada
Takuo Yamai
Kaori Mukai
Tasuku Nakabori
Hiroyuki Uehara
Isao Miyashiro
Kazuyoshi Ohkawa
Publikationsdatum: 18.07.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 14/2023
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-023-04966-x

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Hospital volume and prognosis of patients with metastatic pancreatic cancer: A study using the Osaka Cancer Registry